SEC Tracker
Get the app
AURA · XBRL financial data

Aura Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (AURA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development15,42820,280*17,05216,87917,03622,334*23,34322,88222,17821,897*27,96030,749
General and administrative5,0604,503*5,2615,8836,1965,473*5,6925,7315,7285,340*6,90617,320
Operating income (loss)(20,488)(24,783)*(22,313)(22,762)(23,232)(27,807)*(29,035)(28,613)(27,906)(27,237)*(34,866)(48,069)
Other income (expense)(5)(26)*(32)(26)(25)(37)*(24)(36)(13)149*2154
Income tax expense (benefit)0*137*460*4324*18482615*1129
Net income (loss)(18,512)(22,131)*(19,706)(20,337)(21,042)(25,834)*(27,483)(27,019)(26,130)(25,559)*(33,685)(45,637)
Earnings per share, basic USD per share(0.48)(0.50)*(0.40)(0.41)(0.42)(0.52)*(0.55)(0.47)(0.40)(0.38)*(0.50)(0.48)
Earnings per share, diluted USD per share(0.48)(0.50)*(0.40)(0.41)(0.42)(0.52)*(0.55)(0.47)(0.40)(0.38)*(0.50)(0.48)
Weighted average shares, basic thousands of shares38,18544,596*49,45249,54849,66449,935*50,12658,01665,93767,025*67,44894,863
Weighted average shares, diluted thousands of shares38,18544,596*49,45249,54849,66449,935*50,12658,01665,93767,025*67,44894,863

Balance sheet

CSV

Fiscal quarters (AURA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents55,58441,06326,27930,07525,40731,69338,226107,36747,55359,51584,79367,836
Prepaid and other current assets4,8125,6259,3758,1809,1049,5296,5266,6478,2545,4983,7715,188
Total current assets153,888231,794212,249195,596183,481160,623134,517183,958170,120149,739118,504329,028
Property and equipment, net4,8563,1503,0543,3343,3253,2153,1112,8642,6292,6242,4722,201
Right-of-use asset19,56918,85418,50118,14117,74417,37917,00516,62216,23015,82815,41614,993
Total assets179,766255,075235,025218,282205,340182,503155,401204,397190,024169,430137,677348,129
Accounts payable1,4901,7871,9331,4591,9912,3042,0061,2861,8881,5492,5732,254
Total current liabilities10,89412,3579,66310,54814,71414,91312,16314,85218,82318,38316,70619,560
Lease liability, non-current17,15416,87016,57916,28015,95815,62015,27214,91614,53414,13413,72413,302
Total liabilities28,04829,22726,24226,82830,67230,53327,43529,76833,35732,51730,43032,862
Accumulated deficit(265,177)(287,308)(307,014)(327,351)(348,393)(374,227)(401,710)(428,729)(454,859)(480,418)(514,103)(559,740)
Total stockholders' equity151,718225,848208,783191,454174,668151,970127,966174,629156,667136,913107,247315,267
Total liabilities and equity179,766255,075235,025218,282205,340182,503155,401204,397190,024169,430137,677348,129
Common shares outstanding (cover page) thousands of shares38,26049,50449,54349,60649,95150,22550,26962,12063,50364,150103,387103,705

Cash flows

CSV

Fiscal quarters (AURA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(18,512)(22,131)*(19,706)(20,337)(21,042)(25,834)*(27,483)(27,019)(26,130)(25,559)*(33,685)(45,637)
Stock-based compensation2,325*2,603*2,9093,126*2,750*2,937*3,5143,833*3,688*3,282*3,82412,368*
Net cash from operating activities(15,403)*(17,387)*(24,452)(16,128)*(15,273)*(23,952)*(23,355)(20,774)*(20,144)*(20,469)*(29,893)(32,501)*
Purchases of property and equipment90*317*88525*341*299*18739*45*176*10221*
Net cash from investing activities21,629*(90,120)*9,39619,841*9,889*29,695*29,81319,977*(44,019)*29,824*54,898(226,035)*
Proceeds from issuing common stock————0*0*——0*0*——
Net cash from financing activities1,626*92,985*25383*716*543*9669,929*4,363*2,767*300241,752*
Net change in cash7,852*(14,522)*(14,803)3,796*(4,668)*6,286*——————

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Aura Biosciences67,836not reported(32,501)*103.7M2.1 quarters 10-QJun 30, 2026
Nektar Therapeutics39,26710,131(75,770)*34.1M9.0 quarters 10-QJun 30, 2026
Prothena Corp Public288,1931,010(25,049)*51.3M11.5 quarters 10-QJun 30, 2026
Altimmune63,008not reported(24,221)*194.5M13.5 quarters 10-QJun 30, 2026
Usana Health Sciences168,560223,27323,319*18.5M— 10-QJul 4, 2026
Rigel Pharmaceuticals60,81678,70330,653*18.7M— 10-QJun 30, 2026
Amarin156,51239,5509,223*not reported— 10-QSep 30, 2026
Northwest Biotherapeutics595807(7,169)*1.7B0.1 quarters 10-QJun 30, 2026
Siga Technologies117,58441,00215,174*71.8M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.